Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albumin-bound paclitaxel + nedaplatin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Albumin-bound paclitaxel + nedaplatin is a combination chemotherapy regimen consisting of nab-paclitaxel (albumin-bound paclitaxel) and nedaplatin. Nab-paclitaxel is a nanoparticle, solvent-free formulation of the taxane paclitaxel bound to human serum albumin, which enhances drug delivery and reduces hypersensitivity reactions compared to conventional formulations. It acts as an antimicrotubule agent by promoting microtubule assembly and stabilizing microtubules, thereby inhibiting cell division[2][8]. Nedaplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing tumor cells. This combination has been studied primarily as neoadjuvant or first-line therapy for esophageal squamous cell carcinoma (ESCC) and advanced cervical cancer[1][6][9]. Clinical studies have shown that this regimen offers high objective response rates with manageable toxicity profiles.
- Brand names
- Abraxane
- Other names
- nab-paclitaxel + nedaplatinalbumin-bound paclitaxel plus nedaplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on albumin-bound paclitaxel + nedaplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albumin-bound paclitaxel + nedaplatin.